Early Data In Hand, Vesper Bio Takes On GSK And Alector
Executive Summary
Emerging Company Profile: Danish group Vesper Bio is advancing an oral sortilin inhibitor in frontotemporal dementia, and is aiming to get to market in a similar timeframe to its much larger rivals.